CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma.

Autor:	Pophali PA; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States., Fein JA; Weill Cornell Medicine/NewYork Presbyterian Hospital, New York, New York, United States., Ahn KW; Medical College of Wisconsin, Milwaukee, Wisconsin, United States., Allbee-Johnson M; Medical College of Wisconsin, Milwaukee, Wisconsin, United States., Ahmed N; University of Kansas Cancer Center, Westwood, Kansas, United States., Awan FT; UT Southwestern, Dallas, Texas, United States., Farhan S; Henry Ford Healthsystem, detroit, Michigan, United States., Grover NS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, United States., Hilal T; Mayo Clinic, Phoenix, Arizona, United States., Iqbal M; Mayo Clinic Florida, Jacksonville, Florida, United States., Maakaron J; University of Minnesota, Minneapolis, Minnesota, United States., Modi D; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States., Nasrollahi E; University of Pittsburgh Medical Center in Central PA, Harrisburg, Pennsylvania, United States., Schachter L; University of California Los Angeles, San Luis Obispo, California, United States., Sauter CS; Cleveland Clinic, Cleveland, Ohio, United States., Hamadani M; Medical College of Wisconsin, Wauwatosa, Wisconsin, United States., Herrera AF; City of Hope, Duarte, California, United States., Shouval R; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Shadman M; Fred Hutchinson Cancer Research Center, Seattle, Washington, United States.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2024 Jul 10. Date of Electronic Publication: 2024 Jul 10.
DOI:	10.1182/bloodadvances.2024013863
Abstrakt:	T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19-directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. We investigated CART outcomes for R/R THRLBCL through the CIBMTR registry. A total of 58 adult patients with R/R THRLBCL who received commercial CD19-CART between 2018-2022 were identified. Most patients (67%) had early relapse of disease (45% primary refractory) with a median of 3 (range: 1-7) prior therapies and were treated with Axicabtagene ciloleucel (69%). At median follow-up of 23 months post-CART, 2-year overall and progression-free survival were 42% (95% CI: 27-57) and 29% (95% CI: 17-43), respectively. In univariable analysis, poor performance status pre-CART was associated with higher mortality (HR 2.35, 95%CI 1.02-5.5). The 2-year cumulative incidences of relapse/progression and non-relapse mortality were 69% and 2%, respectively. Grade ≥3 CRS and ICANS occurred in 7% and 15% of patients, respectively. In this largest analysis of CD19-CART for R/R THRLBCL, approximately 30% of patients were alive and progression-free 2 years post-CART. Despite a high incidence of progression (69% at 2 years), these results suggest a subset of patients with R/R THRLBCL may have durable responses with CART. (Copyright © 2024 American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu